PR Web (press release) KAZANO combines alogliptin with metformin HCl, a widely used anti-diabetes medication , in a single tablet. OSENI combines alogliptin with the thiazolidinedione (TZD) pioglitazone, and is the first product in the U.S. to include both a DPP-4i and TZD in ... and more »
The Pharma Letter Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago, includes presentations from US drug majors Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ) and the UK's GlaxoSmithKline (LSE: GSK). Eli ... and more »
4-traders (press release) The active comparators in the studies were insulin, a sulphonylurea (SU), a thiazolidinedione (TZD), and a dipeptidyl peptidase four inhibitor (DPP-4). Albiglutide is not approved for use anywhere in the world. ... Harmony 2 (Abstract number: 2013-LB ... and more »
NASDAQ In the five Harmony studies, albiglutide demonstrated significant efficacy in reducing HbA1c, an indicator of glucose level in the blood, versus placebo and/or active comparators (including insulin, a sulphonylurea, a thiazolidinedione and a dipeptidyl ...
Medscape The thiazolidinedione drug class, which includes rosiglitazone (Avandia, GlaxoSmithKline) as well as pioglitazone, has never been far from controversy. Rosiglitazone was suspended by the European Union in 2010 and its use severely restricted in the ... and more »
FierceBiotech When Onglyza was used in combination with a sulfonylurea or with insulin (two medications known to cause hypoglycemia), the incidence of confirmed hypoglycemia was increased over that of placebo used in combination with a sulfonylurea or with insulin. and more »
Toronto NewsFIX Data was gathered from people on one of three medications for type 2 diabetes – thiazolidinedione, sulfonylurea or metformin. They looked at whether a person had refilled their prescription as a guide to medication adherence. The African American ...
DailyFinance Hypoglycemia: Increased risk of hypoglycemia when used in combination with a sulfonylurea (SFU). Clinicians may consider reducing the SFU dose to minimize risk of hypoglycemia. It is possible that use of BYDUREON with other glucose-independent ...
